Top Tweets for #Posttest

about 2 months ago

@TumorBoardTues @ElizabethSakach @IntegrityCE @dradityabardia @jhaveri_komal @hoperugo #PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME 🔗 https://t.co/Ry1UYxlwB5 🤔What is the preferred option for a 48F, premeno on OFS, with ESR1m HR+/HER2− mBC after AI+CDK4/6i, who has a prolonged QTc and uncontrolled dyslipidemia but can dose fasting and wants an oral Tx❓

192

Shalini Vemuru @ShaliniVemuruMD

about 2 months ago

@TumorBoardTues @ElizabethSakach @IntegrityCE @dradityabardia @jhaveri_komal @hoperugo #PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME Eval 🔗 https://t.co/FbO5M6CgIj 👉🏽ALL CME🔗 https://t.co/Ry1UYxlwB5 ➡️What is the best Tx option for a 64F♀️w/ER+/HER2- mBC; ESR1 D538G, after 26mo on ribo/let and no visceral crisis❓

180

Shalini Vemuru @ShaliniVemuruMD

about 2 months ago

@TumorBoardTues @ElizabethSakach @IntegrityCE @dradityabardia @jhaveri_komal @hoperugo 29/29 #TumorBoardTuesday #OncTwitter Thank you for your attention! #PostTest #TumorBoardTuesday 👉🏽 #CME Eval 🔗 https://t.co/FbO5M6CgIj 👉🏽 ALL CME 🔗 https://t.co/Ry1UYxlwB5

180

Natasha Setia, MD, MS @theGIoncdoc

2 months ago

@TumorBoardTues @DanengLi @IntegrityCE @DanEng #PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME 🔗 https://t.co/INQrmYnzvN 🧑‍⚕️ A patient with embolization-eligible #HCC is being considered for a bevacizumab-containing TACE regimen 🤔 Which baseline review should be prioritized before treatment❓

326

Natasha Setia, MD, MS @theGIoncdoc

2 months ago

@TumorBoardTues @DanengLi @IntegrityCE @DanEng #PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME Eval 🔗 https://t.co/fODoaCviAI 👉🏽ALL CME🔗 https://t.co/INQrmYnzvN 🤔Based on the Ph3 EMERALD-1 (durva+bev+TACE) & LEAP-012 (pembro+lenva+TACE) studies, what do you conclude re: TACE+ICI-based tx vs TACE alone for HCC❓

238

Spencer Lessans @SpenceLessansMD

3 months ago

@TumorBoardTues @CathyEngMD @IntegrityCE #PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME 🔗 https://t.co/hDrH4kl2xV 👉A patient on a zanzalintinib + atezolizumab trial asks what toxicities need close monitoring 🧐Which grade ≥3 AEs were most common in STELLAR-303❓

592

Spencer Lessans @SpenceLessansMD

3 months ago

@TumorBoardTues @CathyEngMD @IntegrityCE #PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME Eval 🔗 https://t.co/2ZabgcRCrI 👉🏽ALL CME🔗 https://t.co/hDrH4kl2xV ➡️58yo man w/MSS/pMMR, RAS/BRAF WT mCRC has POD after FOLFOX/Pani, FOLFIRI/Bev, & TAS-102 🤔Which study Tx regimen improved OS vs regorafenib in STELLAR-303❓

376

Dipesh Uprety MD FACP

@DipeshUpretyMD

4 months ago

@RoupenMD @TumorBoardTues @IntegrityCE #PostTest Q2️⃣#TumorBoardTuesday ➡️67yo♀️w/LS-SCLC completed carbo/etoposide➕🧠☢️8 weeks ago then started durvalumab 🤒She reports new dry cough and dyspnea. Pulse ox is 91% on room air (down from 97%), chest CT shows new inflammatory infiltrates 🧐What is the best next step❓

613

Dipesh Uprety MD FACP

@DipeshUpretyMD

4 months ago

@RoupenMD @TumorBoardTues @IntegrityCE #PostTest Q1️⃣#TumorBoardTuesday 👉🏽#CME Eval 🔗 https://t.co/hkYW7XZIEF 👉🏽ALL CME🔗 https://t.co/vCs5r5zjjX ➡️62yo♂️, PS=1 w/stage IIIA LS-SCLC receives concurrent cis/etoposide➕🫁☢️ 🩻Repeat CT=PR; 🧠MRI is⛔️ for mets 🤔What is the best evidence-based next step❓

584

𝐉𝐨𝐡𝐧-𝐖𝐢𝐥𝐥𝐢𝐚𝐦 𝐒𝐢𝐝𝐡𝐨𝐦, 𝐌𝐃, 𝐏𝐡𝐃

@John_Will_I_Am

4 months ago

@TumorBoardTues @MDmanishshah @IntegrityCE #PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME 🔗 https://t.co/KmtCmAUsYQ 40yo♂️with rectal Ca→liver &🫁mets 🔬 MSS, RAS/RAF WT, HER2 IHC 3+ 📈 PD on FOLFIRI after curative-intent surgery + maintenance 🤔 What 2L would YOU choose today❓

258

April Choi MD

@aprilchoi_md

4 months ago

@TumorBoardTues @SunnieSKim @IntegrityCE @sundar_raghav @YJanjigianMD @KlempnerSam @FilippoPietran4 @sonbol_bassam @GIMedOnc @AnwaarSaeed3 @rutikamehtaMD @ReetuMukherjiMD @NEJM @Senthilsurgonc @M_P_OLeary #PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME 🔗 https://t.co/leBRmFIuyo In MATTERHORN🏔️, adding durvalumab to periop FLOT for resectable gastric/GEJ adenoCa was associated w/ which AE difference vs FLOT alone❓

305

April Choi MD

@aprilchoi_md

4 months ago

@TumorBoardTues @SunnieSKim @IntegrityCE @sundar_raghav @YJanjigianMD @KlempnerSam @FilippoPietran4 @sonbol_bassam @GIMedOnc @AnwaarSaeed3 @rutikamehtaMD @ReetuMukherjiMD @NEJM @Senthilsurgonc @M_P_OLeary #PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME Eval 🔗 https://t.co/AUti1QCMHn 👉🏽ALL CME🔗 https://t.co/leBRmFIuyo 60M w/uT3N2M0, pMMR, HER2-low GEJ adenoCa, ECOG 0 and surgery eligible. Which periop plan improved EFS vs FLOT❓

400

#TumorBoardTuesday

@TumorBoardTues

5 months ago

@NehemiasGuevar5 @NarjustFlorezMD @Latinamd @benlevylungdoc @LealTiciana @MMarmarelis @lungoncdoc @KelseyPanMD @BRicciutiMD @BrunaPellini @ADesaiMD @MPishvaian @dominicandoc2 @DrRoyHerbst @royaryam @IvyLorena_Md @EgfrUk @DFEGFRcenter @EGFRResisters #PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME 🔗 https://t.co/GcuuNjoF1m 🧐 Which statement about 🩸🧬 ctDNA/MRD in resected EGFR+ #NSCLC is most accurate❓

123

#TumorBoardTuesday

@TumorBoardTues

5 months ago

@NehemiasGuevar5 @NarjustFlorezMD @Latinamd @benlevylungdoc @LealTiciana @MMarmarelis @lungoncdoc @KelseyPanMD @BRicciutiMD @BrunaPellini @ADesaiMD @MPishvaian @dominicandoc2 @DrRoyHerbst @royaryam @IvyLorena_Md @EgfrUk @DFEGFRcenter @EGFRResisters #PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME Eval 🔗 https://t.co/62THW0Ot1q 👉🏽ALL CME🔗 https://t.co/GcuuNjoF1m ➡️61yo🚭undergoes sugery🔪for a stage IIB🫁AdenoCa➕EGFR exon 19 del followed by adj cis/pem 🤔Most evidence-based next step❓

147

Karine Tawagi MD @DrKarineTawagi

6 months ago

#PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME 🔗 https://t.co/Mzcx6hoJkk 🤔Which of the following is a preferred approach for patients with muscle-invasive bladder cancer with low renal function❓ @PGrivasMDPhD @TumorBoardTues @OncBrothers @TwoOncDocs @tompowles1 @AmandaNizamMD

869

Karine Tawagi MD @DrKarineTawagi

6 months ago

#PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME Eval 🔗 https://t.co/wSgHHQvg3L 👉🏽ALL CME🔗 https://t.co/Mzcx6hoJkk 🤔Which is a preferred PeriOp Tx for a fit cisplatin-eligible patient with muscle-invasive bladder cancer❓ @PGrivasMDPhD @TumorBoardTues @OncBrothers @TwoOncDocs